Navigation Links
Bavarian Nordic Publishes its Annual Results 2008

contract. In 2009 we will have a continued strong focus on fulfilling this contract as well as a strong focus on preparing for the Phase III studies that we expect to initiate with both IMVAMUNE(R) and PROSTVAC(TM) in 2010."

Strong foundation for future growth and earnings

Despite the financial crisis and an economic slowdown, Bavarian Nordic recorded a positive development in 2008, and has laid a strong foundation for further value creation in 2009 and the years ahead. The expected positive development is based on the following elements:

    - Two vaccines moving into Phase III trials

    - Strong financial position

    - Profitable ongoing development and procurement contracts with a value
      of more than DKK 3.5 billion

    - Expectations to the US government's exercise of the contract option for
      additional development and procurement, worth more than DKK 6 billion

    - Ongoing contracts with countries outside USA

    - Partnership with the NCI, a world leading cancer research organisation

    - Strong patent portfolio

    - Pipeline with promising results

    - Future licensing agreement for PROSTVAC(TM)

    - The world's only manufacturing facility dedicated to the
      commercial-scale production of MVA based vaccines

    Important events after the balance sheet date
    IMVAMUNE(R) - end-of-Phase II meeting held with the FDA

After concluding the Phase II development of IMVAMUNE(R), Bavarian Nordic held an end-of-Phase-II meeting with the US health authorities (FDA) in the beginning of 2009 in order to discuss the Phase III study design. The meeting was a success and there was an open and highly constructive discussion with the FDA. Based on the meeting, Phase III studies are expected to be initiated in 2010.

The outcome of the meeting has no impact on the delivery of vaccines to the Strategic National Stockpile (SNS) under the RFP-

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
(Date:9/18/2014)... a new microscopy technology that allows them to ... resolution. , Dubbed "Complementation Activated Light Microscopy" (CALM), ... an order of magnitude finer than conventional optical ... biomolecules at the nanometer scale. , In a ... Communications , the researchers behind CALM used it ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... the latest addition to Clinovo’s CRO Partnership Program. With ... Program, Clinovo further expands its global reach to Latin ... we are now able to build studies on our ... also rely on Clinovo to fully support the solution ...
(Date:9/18/2014)... Whitehouse Laboratories is pleased to announce that ... has acquired an additional 4,000 square feet of dedicated ... adjacent to its current package testing facility. The official ... Whitehouse Labs is in the process of upgrading the ... testing. The prime location enables Whitehouse Labs to immediately ...
(Date:9/17/2014)... LONDON , Sept. 17, 2014 The global ... Tons by 2019. Squalene is a natural skin-identical chemical that ... & personal care, food supplements, pharmaceuticals, and in other applications ... The squalene market has a few major players and is ... (U.S.), Kishimoto Special Liver Oil Co. Ltd. ( Japan ...
Breaking Biology Technology:Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3
... an effort to spur entrepreneurship in a broader range ... has named the University of Wisconsin-Madison as ... has received $5 million to help train students in ... in 2004 to bring entrepreneurship education to a wider ...
... to provide end-to-end approach to retail workforce optimization ... and the Denver-based StorePerform Technologies, Inc. , ,The ... in the next 20 to 30 days. Financial terms were ... part of RedPrairie's retail productivity division, previously known as ...
... this is my last article of the year, and I have ... my New Year's resolution for this column is bring back more ... is that I simply have not gone to as many concerts ... will need to remedy!) , ,Looking over 2006, my focus has ...
Cached Biology Technology:UW gets $5M to extend entrepreneurship 22006: A great biotech financing year, unless you were going public! 22006: A great biotech financing year, unless you were going public! 32006: A great biotech financing year, unless you were going public! 42006: A great biotech financing year, unless you were going public! 5
(Date:9/17/2014)... EC-FP5 four-year project, delivering its first release in 2004. ... in several EC projects, as a part of the ... BON), to increase the general awareness of the work ... dissemination of the Fauna Europaea results, the ... e-Publishing tools to prepare data papers for all 56 ...
(Date:9/17/2014)... Copenhagen Centre for Social Evolution and Yale University offers ... weight and -length can partially predict the likelihood of ... and schizophrenia later in life. The study analyzed medical ... diagnoses for up to 30 years, and adjusted for ... published today in the Proceedings of the Royal ...
(Date:9/17/2014)... EAST LANSING, Mich. Mutations in the human retinoblastoma ... Now, Michigan State University scientists have turned to fruit ... cancer gene. , In a paper featured on ... Journal of Biological Chemistry , Michigan State University researchers ... mutations similar to those present in the human cancer ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Abnormal properties of cancer protein revealed in fly eyes 2
... , This news release is available in ... diseases like Parkinson,s disease involve the death of thousands of neurons ... as GDNF, promote the survival of the neurons; however, clinical tests ... the Max Planck Institute of Neurobiology in Martinsried and their colleagues ...
... year around 11 million people suffer severe burns. The resulting ... results in lifelong scars. What is needed to reduce this ... Only a very limited area of skin can be removed ... new wounds. Besides conventional skin grafting, another option is to ...
... synthetic biology will be established in Bristol, Nottingham ... from the Biotechnology and Biological Sciences Research Council ... Council (EPSRC). The 40M+ investment will be ... David Willetts tonight at a BBSRC event in ...
Cached Biology News:Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3Blood and lymphatic capillaries grown for the first time in the lab 2UK establishes 3 new synthetic biology research centers 2
... products ATP-Free using Mo Bio luciferase assay. Mo ... service that will allow you to certify your ... and enable you to deliver them to your ... ATP detection limit is 3.5 x 10-12 /l, ...
... in Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, ... Germany) have collaborated to develop a fluorescence ... The DNAscope AT is based on ... AT automatically reads up to six ArrayTubes ...
... provides a comprehensive kinase analysis service ... (PKS) peptide microarrays synthesized on Paraflo ... profiling, quantitative measurement of kinase kinetic ... comprehensive service includes preparation of your ...
... The JNK (c-Jun NH2-terminal kinase) signal ... identified MAP kinase pathways in mammals. ... to environmental stress, is associated with ... and is implicated in the immune ...
Biology Products: